-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
RenovoRx (NASDAQ:RNXT) Stock Price Down 7.6%
RenovoRx (NASDAQ:RNXT) Stock Price Down 7.6%
RenovoRx, Inc. (NASDAQ:RNXT – Get Rating)'s stock price traded down 7.6% during trading on Wednesday . The stock traded as low as $3.54 and last traded at $3.65. 354,715 shares traded hands during trading, an increase of 346% from the average session volume of 79,574 shares. The stock had previously closed at $3.95.
RenovoRx Stock Performance
The company has a market cap of $33.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The stock's fifty day moving average is $2.23 and its two-hundred day moving average is $2.13.
Get RenovoRx alerts:RenovoRx (NASDAQ:RNXT – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that RenovoRx, Inc. will post -1.11 EPS for the current year.
Hedge Funds Weigh In On RenovoRx
Large investors have recently bought and sold shares of the stock. Colony Group LLC purchased a new stake in shares of RenovoRx in the third quarter valued at about $32,000. Vanguard Group Inc. bought a new position in shares of RenovoRx during the 1st quarter worth approximately $32,000. Bank of America Corp DE bought a new position in shares of RenovoRx in the first quarter valued at approximately $44,000. Cohen Lawrence B increased its position in shares of RenovoRx by 79.5% during the second quarter. Cohen Lawrence B now owns 97,165 shares of the company's stock valued at $192,000 after acquiring an additional 43,044 shares during the last quarter. Finally, Bank of The West bought a new stake in RenovoRx during the second quarter worth $1,931,000. 13.56% of the stock is currently owned by institutional investors.RenovoRx Company Profile
(Get Rating)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Featured Stories
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
RenovoRx, Inc. (NASDAQ:RNXT – Get Rating)'s stock price traded down 7.6% during trading on Wednesday . The stock traded as low as $3.54 and last traded at $3.65. 354,715 shares traded hands during trading, an increase of 346% from the average session volume of 79,574 shares. The stock had previously closed at $3.95.
RenoorX 公司 (納斯達克:RNXT — 獲得評級) 的股票價格在星期三交易期間下跌 7.6%。該股價低至 3.54 美元，最後成交價為 3.65 美元。354,715 股在交易過程中交易手數，較 79,574 股的平均交易量上升 346%。該股票之前已收盤 3.95 美元。
RenovoRx Stock Performance
雷諾科技股票表現
The company has a market cap of $33.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The stock's fifty day moving average is $2.23 and its two-hundred day moving average is $2.13.
該公司的市值為 33.11 萬美元，價格與收益比為 -3.72，測試版為 0.25。該股票的五十天移動平均線為 2.23 美元，其 200 日移動平均線為 2.13 美元。
RenovoRx (NASDAQ:RNXT – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that RenovoRx, Inc. will post -1.11 EPS for the current year.
雷諾沃克 (NASDAQ: RNXT — 獲得評分) 最近一次發佈其季度盈利數據，日期為 11 月 14 日，星期一。該公司報告了本季每股盈利（0.24 美元），超過 0.27 美元的共識估計（0.27 美元）0.03 美元。平均而言，股票研究分析師預計 RenoorX 公司將在本年度每股盈利 -1.11。
Hedge Funds Weigh In On RenovoRx
對沖基金權衡雷諾
RenovoRx Company Profile
瑞諾公司簡介
(Get Rating)
(取得評分)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
RenoorX, Inc 是一家臨床階段生物製藥公司，專注於開發用於治療實體瘤的療法。其主要候選產品是 ReNovogem，這是一種由動脈內吉西他濱和 ReNovoCath 組成的藥物和器件組合，該藥物和器件組合在局部晚期胰腺癌的 III 期臨床試驗中。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 獲取有關雷諾沃克斯（RNXT）的研究報告的免費副本
- 寶潔公司的收益：值得參加的賭博
- 股票幻燈片，經濟報告描繪經濟陰沉的圖片
- NU 控股股票與沃倫·巴菲特有什麼關係？
- J.B. 亨特得到一個單位, 物流公司成為焦點
- 英特爾股票是否瀕臨爆發？
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收 RenoorX 每日最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 RenoorX 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧